JPH10513185A - ミセル性ナノ粒子 - Google Patents
ミセル性ナノ粒子Info
- Publication number
- JPH10513185A JPH10513185A JP8523735A JP52373596A JPH10513185A JP H10513185 A JPH10513185 A JP H10513185A JP 8523735 A JP8523735 A JP 8523735A JP 52373596 A JP52373596 A JP 52373596A JP H10513185 A JPH10513185 A JP H10513185A
- Authority
- JP
- Japan
- Prior art keywords
- micellar
- nanoparticles
- oil
- initiator
- oils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 64
- 239000003999 initiator Substances 0.000 claims abstract description 33
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 31
- 229960005309 estradiol Drugs 0.000 claims abstract description 31
- 229930182833 estradiol Natural products 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000003921 oil Substances 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 239000002245 particle Substances 0.000 claims description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 235000019198 oils Nutrition 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 12
- 239000012071 phase Substances 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 11
- 239000000693 micelle Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- -1 fish oils Substances 0.000 claims description 7
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000010699 lard oil Substances 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 235000019488 nut oil Nutrition 0.000 claims description 3
- 239000010466 nut oil Substances 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 229940013317 fish oils Drugs 0.000 claims description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 2
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 abstract description 11
- 230000001476 alcoholic effect Effects 0.000 abstract description 2
- 230000000887 hydrating effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 11
- 238000000635 electron micrograph Methods 0.000 description 6
- 238000004513 sizing Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GFURAIPDNXHHQY-WAJSLEGFSA-N CCO.OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 Chemical compound CCO.OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 GFURAIPDNXHHQY-WAJSLEGFSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Colloid Chemistry (AREA)
- Cosmetics (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.約25〜1000nmの直径を有するミセル性ナノ粒子であって、該ミセル 性ナノ粒子が、油、安定剤及びアルコールベースの開始剤を含み適当な水ベース の溶液で水和された親油相を含み、該安定剤を、ツイーン60、ツイーン80、 ノニルフェノールポリエチレングリコールエーテル及びこれらの混合物よりなる 群から選択する、上記のミセル性ナノ粒子。 2.前記の開始剤を、メタノール、エタノール及びこれらの混合物を含むアルコ ールベースの物質よりなる群から選択する、請求項1に記載のミセル性ナノ粒子 。 3.前記の開始剤を、50%以上のエタノール、メタノール及びこれらの混合物 を含むアルコールベースの物質よりなる群から選択する、請求項2に記載のミセ ル性ナノ粒子。 4.前記の油を、植物油、堅果油、魚油、ラード油、鉱油、スクアラン、トリカ プリリン及びこれらの混合物よりなる群から選択する、請求項1に記載のミセル 性ナノ粒子。 5.前記の水溶液が生理学的に適合性の溶液を含む、請求項1に記載のミセル性 ナノ粒子。 6.前記の水溶液を、水及びリン酸緩衝塩溶液よりなる群から選択する、請求項 8に記載のミセル性ナノ粒子。 7.前記の水相がそれに溶解させ又は懸濁させた活性物質を有する、請求項1に 記載のミセル性ナノ粒子。 8.前記の油がそれに溶解させ又は懸濁させた活性物質を有する、請求項1に記 載のミセル性ナノ粒子。 9.前記の開始剤がそれに溶解させ又は懸濁させた活性物質を有する、請求項1 に記載のミセル性ナノ粒子。 10.前記の活性物質がエストラジオールを含む、請求項9に記載のミセル性ナ ノ粒子。 11.前記のミセル性ナノ粒子が水溶液に分散可能である、請求項1に記載のミ セル性ナノ粒子。 12.前記のミセル性ナノ粒子の直径が0.2mmのフィルターの通過を可能に する、請求項1に記載のミセル性ナノ粒子。 13.下記のステップを含む、ミセル性ナノ粒子の製造方法: 過剰の油を安定剤及び開始剤とブレンドして親油相を形成し、該安定剤は、ツ イーン60、ツイーン80、ノニルフェノールポリエチレングリコールエーテル 及びこれらの混合物よりなる群から選択し; 水溶液ベースを有する稀釈溶液を調製し;そして 過剰の該親油相を該稀釈剤とブレンドして上記のミセル性ナノ粒子を形成する 。 14.前記の開始剤を、メタノール、エタノール及びこれらの混合物を含むアル コールベースの物質よりなる群から選択する、請求項13に記載の方法。 15.前記の開始剤を、50%以上のエタノール、メタノール及びこれらの混合 物を含むアルコールベースの物質よりなる群から選択する、請求項14に記載の 方法。 16.前記の油を、植物油、堅果油、魚油、ラード油、鉱油、スクアラン、トリ カプリリン及びこれらの混合物よりなる群から選択する、請求項13に記載の方 法。 17.前記の水溶液が生理学的に適合性の溶液を含む、請求項16に記載の方法 。 18.前記の水溶液を、水及びリン酸緩衝塩溶液よりなる群から選択する、請求 項17に記載の方法。 19.前記の水相がそれに溶解させ又は懸濁させた活性物質を有する、請求項1 3に記載の方法。 20.前記の油がそれに溶解させ又は懸濁させた活性物質を有する、請求項13 に記載の方法。 21.前記の開始剤がそれに溶解させ又は懸濁させた活性物質を有する、請求項 13に記載の方法。 22.前記の活性物質がエストラジオールを含む、請求項21に記載の方法。 23.前記の親油相と前記の希釈剤とのブレンディングを、約50m/sの相対 速度を用いて、1/18,000インチのオリフィスを通して達成する、請求項 13に記載の方法。 24.前記の親油相の前記の水相に対する比が約4:1である、請求項13に記 載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/380,942 US5629021A (en) | 1995-01-31 | 1995-01-31 | Micellar nanoparticles |
| US08/380,942 | 1995-01-31 | ||
| PCT/US1996/001410 WO1996023409A1 (en) | 1995-01-31 | 1996-01-29 | Micellar nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10513185A true JPH10513185A (ja) | 1998-12-15 |
| JP3974170B2 JP3974170B2 (ja) | 2007-09-12 |
Family
ID=23503042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52373596A Expired - Fee Related JP3974170B2 (ja) | 1995-01-31 | 1996-01-29 | ミセル性ナノ粒子 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5629021A (ja) |
| EP (1) | EP0806894B1 (ja) |
| JP (1) | JP3974170B2 (ja) |
| KR (1) | KR100482390B1 (ja) |
| CN (1) | CN1144583C (ja) |
| AU (1) | AU711744B2 (ja) |
| BR (1) | BR9606996A (ja) |
| CA (1) | CA2211262C (ja) |
| DE (1) | DE69627309T2 (ja) |
| DK (1) | DK0806894T3 (ja) |
| ES (1) | ES2200055T3 (ja) |
| PT (1) | PT806894E (ja) |
| WO (1) | WO1996023409A1 (ja) |
| ZA (1) | ZA96738B (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009533341A (ja) * | 2006-04-07 | 2009-09-17 | ノババックス,インコーポレイテッド | 抗細菌、抗真菌、抗酵母、および/または抗ウイルス特性を有するナノ構造組成物 |
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387373B1 (en) * | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
| US6542183B1 (en) | 1995-06-28 | 2003-04-01 | Lynx Systems Developers, Inc. | Event recording apparatus |
| US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US6958148B1 (en) * | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
| KR100342835B1 (ko) * | 1998-07-31 | 2002-07-02 | 박호군 | 유전자 또는 약물을 효과적으로 전달하는 지방유제, 제형 및 이들의 제조방법 |
| US6284234B1 (en) * | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| US20020054914A1 (en) * | 1999-02-03 | 2002-05-09 | Tulin Morcol | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein |
| US20040258763A1 (en) * | 1999-02-03 | 2004-12-23 | Bell Steve J.D. | Methods of manufacture and use of calcium phosphate particles containing allergens |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7655252B2 (en) | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US8236335B2 (en) | 1999-04-28 | 2012-08-07 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス, インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| ATE485837T1 (de) | 2000-08-03 | 2010-11-15 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert |
| US6423707B1 (en) | 2000-08-28 | 2002-07-23 | California Pacific Medical Center | Nitroimidazole ester analogues and therapeutic applications |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US6537591B2 (en) | 2001-03-02 | 2003-03-25 | Aquarium Pharmaceuticals, Inc. | Aquatic animal treatment method and composition containing Pimenta extract |
| US20030185892A1 (en) * | 2001-08-17 | 2003-10-02 | Bell Steve J. D. | Intraocular delivery compositions and methods |
| BR0212163A (pt) * | 2001-08-28 | 2004-12-07 | Eden Reseaech Plc | Composição para tratamento ou prevenção de infecção em plantas |
| US6878693B2 (en) | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
| US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
| US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8663687B2 (en) * | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
| US20030180349A1 (en) * | 2001-12-07 | 2003-09-25 | Franklin Lanny U. | Respiratory infection prevention and treatment with terpene-containing compositions |
| US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
| AU2003223183A1 (en) * | 2002-02-19 | 2003-09-09 | Eden Researach Plc | Improvement of indoor air quality and antiseptic composition for use therein |
| WO2003070181A2 (en) * | 2002-02-19 | 2003-08-28 | Eden Research Plc | Compositions and methods for preservation of food |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| US20040087564A1 (en) * | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
| US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
| ATE534373T1 (de) | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| US20050084513A1 (en) * | 2003-10-21 | 2005-04-21 | Board Of Regents | Nanocoating for improving biocompatibility of medical implants |
| US20050084456A1 (en) * | 2003-10-21 | 2005-04-21 | Liping Tang | Functionalized particles |
| PT3659437T (pt) | 2004-01-23 | 2022-06-20 | Eden Research Plc | Métodos para matar nemátodos que compreendem a aplicação de um componente terpeno encapsulado |
| US7651694B2 (en) * | 2004-02-13 | 2010-01-26 | Nod Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of making and using same |
| US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| EP2338332B1 (en) | 2004-05-20 | 2014-02-12 | Eden Research Plc | Hollow glucan particle or cell wall particle encapsulating a terpene component |
| US20060067977A1 (en) | 2004-09-28 | 2006-03-30 | Atrium Medical Corporation | Pre-dried drug delivery coating for use with a stent |
| US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
| EP1811935B1 (en) | 2004-09-28 | 2016-03-30 | Atrium Medical Corporation | Heat cured gel and method of making |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| CA2586035A1 (en) * | 2004-11-01 | 2006-05-11 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| WO2006113668A1 (en) * | 2005-04-15 | 2006-10-26 | University Of South Florida | A method of transdermal drug delivery using hyaluronic acid nanoparticles |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| US20080274195A1 (en) | 2005-07-18 | 2008-11-06 | University Of Massachusetts Lowell | Compositions and Methods for Making and Using Nanoemulsions |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| GEP20125432B (en) | 2005-10-12 | 2012-03-26 | Unimed Pharmaceuticals Llc | Improved testosterone gel and use thereof |
| KR101359723B1 (ko) | 2005-10-18 | 2014-02-05 | 노바백스, 인코포레이티드 | 기능성 인플루엔자 바이러스 유사 입자들 |
| EP2982244B1 (en) | 2005-11-30 | 2020-11-18 | Eden Research Plc | Insecticidal capsules containing thymol and methods of making and using them |
| JP6027718B2 (ja) | 2005-11-30 | 2016-11-16 | エーデン リサーチ ピーエルシー | チモール、オイゲノール、ゲラニオール、シトラール、及びl−カルボンから選択されたテルペン又はテルペン混合物を含む組成物及び方法 |
| KR102110379B1 (ko) | 2005-12-01 | 2020-05-14 | 유니버시티 오브 메사츄세츠 로웰 | 보툴리눔 나노에멀젼 |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| EP2001439A2 (en) * | 2006-03-07 | 2008-12-17 | Novavax, Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
| US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
| CN101426475A (zh) * | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
| US9040250B2 (en) * | 2006-09-07 | 2015-05-26 | The United States Of America, As Represented By The Secretary Of The Navy | Binding interaction of proanthocyanidins with bacteria and bacterial components |
| US20080139513A1 (en) * | 2006-09-26 | 2008-06-12 | Novavax, Inc. | Transdermal deliver of active agents |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| SG177184A1 (en) | 2006-12-01 | 2012-01-30 | Anterios Inc | Amphiphilic entity nanoparticles |
| SG179457A1 (en) | 2006-12-01 | 2012-04-27 | Anterios Inc | Peptide nanoparticles and uses therefor |
| WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
| US20080207756A1 (en) * | 2007-02-27 | 2008-08-28 | Atrium Medical Corporation | Bio-absorbable oil suspension |
| WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| CN101765423B (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
| US20110008838A1 (en) | 2007-07-19 | 2011-01-13 | Gale Smith | Chimeric varicella zoster virus virus-like particles |
| KR101848095B1 (ko) * | 2008-06-26 | 2018-04-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| CA2743904A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
| PL2370099T3 (pl) | 2008-12-09 | 2016-10-31 | Zmodyfikowane białka F RSV i sposoby ich zastosowania | |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| SG10201401297QA (en) | 2009-04-08 | 2014-08-28 | Cadila Healthcare Ltd | Stable pharmaceutical compositions of diclofenac |
| US8470304B2 (en) | 2009-08-04 | 2013-06-25 | Avidas Pharmaceuticals Llc | Therapeutic vitamin D sun-protecting formulations and methods for their use |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US20110045050A1 (en) * | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
| US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| US9789123B2 (en) | 2010-10-21 | 2017-10-17 | Cadila Healthcare Limited | Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis |
| US20130295145A1 (en) | 2010-10-21 | 2013-11-07 | Cadila Healthcare Limited | Topical pharmaceutical compositions comprising etodolac |
| US10028972B2 (en) | 2010-10-21 | 2018-07-24 | Cadila Healthcare Limited | Pharmaceutical compositions of anti-acne agents |
| MX2013004296A (es) | 2010-10-21 | 2013-09-26 | Cadila Healthcare Ltd | Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis. |
| WO2012053012A2 (en) | 2010-10-21 | 2012-04-26 | Cadila Healthcare Limited | Topical pharmaceutical compositions comprising tfflocolchicoside |
| WO2012053009A2 (en) | 2010-10-21 | 2012-04-26 | Cadila Healthcare Limited | Pharmaceutical compositions comprising skin whitening agents |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| WO2012059936A1 (en) | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
| KR101847908B1 (ko) | 2010-11-05 | 2018-04-11 | 노바백스, 인코포레이티드 | 광견병 당단백질 바이러스-유사 입자(VLPs) |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| EP3263121B1 (en) | 2010-12-21 | 2019-02-27 | Leidos, Inc. | Methods and compositions for wound treatment |
| US20120189677A1 (en) * | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
| WO2012127496A1 (en) | 2011-03-01 | 2012-09-27 | Cadila Healthcare Limited | Stable pharmaceutical compositions of lornoxicam or salts thereof |
| US11065206B2 (en) | 2011-06-29 | 2021-07-20 | Avidas Pharmaceuticals, LLC | Topical formulations including lipid microcapsule delivery vehicles and their uses |
| WO2013014680A1 (en) | 2011-07-28 | 2013-01-31 | Cadila Healthcare Limited | Method for treatment of pain and inflammation |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10322089B2 (en) * | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| GB201220940D0 (en) | 2012-11-21 | 2013-01-02 | Eden Research Plc | Method P |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| BR112016006122B1 (pt) | 2013-09-19 | 2023-11-14 | Novavax, Inc | COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV) |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| CN111700877A (zh) | 2014-09-03 | 2020-09-25 | 吉倪塞思公司 | 治疗性纳米粒子和相关的组合物、方法和系统 |
| US10894024B2 (en) * | 2014-12-08 | 2021-01-19 | Synaptamine, Inc. | Anti-RDS compounds and method of manufacture and administration thereof to induce dopamine homeostatis |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CA2996007A1 (en) | 2015-09-03 | 2017-03-09 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| WO2017192921A1 (en) | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
| MX2019005833A (es) | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
| US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| JP7317796B2 (ja) | 2017-07-24 | 2023-07-31 | ノババックス,インコーポレイテッド | 呼吸器疾患を治療するための方法および組成物 |
| WO2020018974A1 (en) | 2018-07-20 | 2020-01-23 | Lipocine Inc. | Liver disease |
| CN110881462A (zh) * | 2019-11-25 | 2020-03-17 | 南京启佑生物科技有限公司 | 一种基于磷酸盐与金属离子的纳米农药复合制剂及其制备方法 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| US20250085282A1 (en) | 2023-09-11 | 2025-03-13 | Novavax, Inc. | Method for detecting anti-sars-cov-2 spike (s) immunoglobulins |
| US20250144200A1 (en) | 2023-11-06 | 2025-05-08 | Novavax, Inc. | Intranasal immunogenic compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4182330A (en) * | 1977-07-25 | 1980-01-08 | Alza Corporation | Means for administering amphipathic medicament |
| US4356167A (en) * | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| DE3161962D1 (en) * | 1980-07-01 | 1984-02-23 | Oreal | Process for obtaining stable dispersions in an aqueous phase of at least a water immiscible liquid phase, and corresponding dispersions |
| US4725442A (en) * | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
| US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4824675A (en) * | 1987-07-13 | 1989-04-25 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
| DE3919982A1 (de) * | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | Orale lipidarzneiform |
| CH677886A5 (ja) * | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
| AU658608B2 (en) * | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
-
1995
- 1995-01-31 US US08/380,942 patent/US5629021A/en not_active Expired - Lifetime
-
1996
- 1996-01-29 ES ES96906271T patent/ES2200055T3/es not_active Expired - Lifetime
- 1996-01-29 JP JP52373596A patent/JP3974170B2/ja not_active Expired - Fee Related
- 1996-01-29 KR KR1019970705166A patent/KR100482390B1/ko not_active Expired - Fee Related
- 1996-01-29 AU AU49709/96A patent/AU711744B2/en not_active Ceased
- 1996-01-29 WO PCT/US1996/001410 patent/WO1996023409A1/en not_active Ceased
- 1996-01-29 DK DK96906271T patent/DK0806894T3/da active
- 1996-01-29 CN CNB96192912XA patent/CN1144583C/zh not_active Expired - Fee Related
- 1996-01-29 DE DE69627309T patent/DE69627309T2/de not_active Expired - Lifetime
- 1996-01-29 CA CA002211262A patent/CA2211262C/en not_active Expired - Fee Related
- 1996-01-29 PT PT96906271T patent/PT806894E/pt unknown
- 1996-01-29 BR BR9606996A patent/BR9606996A/pt not_active Application Discontinuation
- 1996-01-29 EP EP96906271A patent/EP0806894B1/en not_active Expired - Lifetime
- 1996-01-31 ZA ZA96738A patent/ZA96738B/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009533341A (ja) * | 2006-04-07 | 2009-09-17 | ノババックス,インコーポレイテッド | 抗細菌、抗真菌、抗酵母、および/または抗ウイルス特性を有するナノ構造組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100482390B1 (ko) | 2005-08-31 |
| EP0806894A4 (en) | 1999-12-15 |
| ES2200055T3 (es) | 2004-03-01 |
| CA2211262A1 (en) | 1996-08-08 |
| MX9705663A (es) | 1998-07-31 |
| US5629021A (en) | 1997-05-13 |
| AU4970996A (en) | 1996-08-21 |
| JP3974170B2 (ja) | 2007-09-12 |
| WO1996023409A1 (en) | 1996-08-08 |
| DE69627309D1 (de) | 2003-05-15 |
| KR19980701770A (ko) | 1998-06-25 |
| DK0806894T3 (da) | 2003-08-04 |
| CA2211262C (en) | 2005-08-30 |
| CN1179698A (zh) | 1998-04-22 |
| PT806894E (pt) | 2003-08-29 |
| EP0806894B1 (en) | 2003-04-09 |
| ZA96738B (en) | 1996-09-26 |
| AU711744B2 (en) | 1999-10-21 |
| CN1144583C (zh) | 2004-04-07 |
| EP0806894A1 (en) | 1997-11-19 |
| DE69627309T2 (de) | 2004-03-04 |
| BR9606996A (pt) | 1997-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3974170B2 (ja) | ミセル性ナノ粒子 | |
| Kantarcı et al. | Comparison of different water/oil microemulsions containing diclofenac sodium: preparation, characterization, release rate, and skin irritation studies | |
| TWI290052B (en) | Emulsion vehicle for poorly soluble drugs | |
| CA1282405C (en) | Method for making uniformly sized particles from water-insoluble organic compounds | |
| EP0130577B2 (en) | Method for producing liposomes | |
| AU684460B2 (en) | Topical and transdermal delivery system utilizing submicron oil spheres | |
| DE19856432A1 (de) | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen | |
| JPH10500675A (ja) | マイクロエマルションを基礎にしたゲルから由来する医薬組成物、その製造方法および新規なマイクロエマルションを基礎にしたゲル | |
| JPS63150221A (ja) | 結晶性薬物含有乳化組成物 | |
| AU2002218498B2 (en) | W/O/W composite emulsion | |
| Shekhawat | Preparation and evaluation of clotrimazole nanostructured lipid carrier for topical delivery | |
| KR102813285B1 (ko) | 바쿠치올이 봉입된 NLC(Nanostructured Lipid Carriers)를 유효성분으로 함유하는 화장료 조성물 | |
| CN107106421A (zh) | 表皮生长因子和脂质体的混合型多层纳米结构及其制造方法 | |
| AU771977B2 (en) | Media in the form of complex dispersions, method for preparing same and uses | |
| DE69130832T2 (de) | Injizierbare amphotericin b enthaltende dispersion | |
| CA2238263A1 (en) | Cortisone spray for topical administration | |
| OKOCHI et al. | Basic studies on formulation, method of preparation and characterization of water-in-oil-in-water type multiple emulsions containing vancomycin | |
| CN112263542B (zh) | 地奈德纳米乳凝胶组合物及其制备方法 | |
| KR101827611B1 (ko) | 피코시아닌을 포함하는 유중수 마이크로 또는 나노에멀젼 | |
| Türkyılmaz et al. | Physical characterization and stability of a microemulsion for potential oral administration of a peptide | |
| MXPA97005663A (en) | Nanoparticulas micela | |
| Annisa et al. | Preparation and characterization of marigolds (Cosmos caudatus L.) leaf extract-loaded nanoemulsion: physicochemical properties and in-vitro release activities of nanoemulsion system using virgin coconut oil (VCO) | |
| KR101054728B1 (ko) | 난용성 발모 및 육모 생리활성 물질인 사이클로스포린을포함하는 나노입자 및 이를 함유하는 피부 외용제 조성물 | |
| Woo | Formulation and physicochemical properties of macro-and microemulsions prepared by interfacial ion-pair formation between amino acids and fatty acids | |
| HK1235705B (zh) | 表皮生长因子和脂质体的混合型多层纳米结构及其制造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061205 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070305 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070515 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070614 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100622 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |